New Year Bumper Sale @ Rs. 1 X
Ruparib brand contains Rucaparib is an orally available poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain types of ovarian, prostate, and other cancers. It is designed to exploit deficiencies in DNA repair mechanisms, particularly in patients with BRCA1/BRCA2 mutations and other homologous recombination deficiencies (HRD).
Rucaparib works by inhibiting PARP enzymes (PARP-1, PARP-2, and PARP-3), which are involved in DNA repair through the base excision repair pathway. By blocking these enzymes, rucaparib prevents the repair of single-strand DNA breaks, leading to the accumulation of double-strand breaks.
Rucaparib is a promising PARP inhibitor that has demonstrated effectiveness in ovarian and prostate cancers, particularly in patients with BRCA mutations. Its mechanism of action makes it a valuable option for patients with homologous recombination deficiency (HRD).
However, due to potential side effects such as bone marrow suppression, liver toxicity, and secondary cancers, regular monitoring and dose modifications are crucial. With ongoing clinical trials exploring additional indications, rucaparib may expand its role in precision oncology. For patients with platinum-sensitive ovarian cancer or mCRPC, rucaparib provides a targeted, oral treatment option that helps delay disease progression and improve outcomes.
Rucaparib is metabolized mainly by CYP enzymes (CYP2C19, CYP3A4), so caution is needed when co-administering with drugs that:
Patients should inform their healthcare providers about all medications and supplements they are taking to avoid adverse interactions.
Ruparib is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Female) |
|
Geriatric |
|
Is the use of Ruparib safe for pregnant women?
It is not known what effect Ruparib will have on pregnant women, because no research work has been carried out on this till date.
Is the use of Ruparib safe during breastfeeding?
Information about safety of Ruparib for women who are breastfeeding is not available since scientific research on this is yet to be done.
What is the effect of Ruparib on the Kidneys?
Information about safety of Ruparib for kidney is not available since scientific research on this topic is yet to be done.
What is the effect of Ruparib on the Liver?
Side effects of Ruparib on the liver are unknown because research on this has not been conducted yet.
What is the effect of Ruparib on the Heart?
Side effects of Ruparib on heart are unknown because research on this has not been conducted yet.
Ruparib should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Ruparib unless your doctor advises you to do so -
Is this Ruparib habit forming or addictive?
Ruparib is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Ruparib. So it is best to avoid driving.
Is it safe?
Yes, but take Ruparib only as per medical advice.
Is it able to treat mental disorders?
No, Ruparib is not used to treat mental disorders.
Interaction between Food and Ruparib
Due to the absence of research, it is difficult to say how Ruparib and food will interact.
Interaction between Alcohol and Ruparib
No research has been done on this till date. Therefore, it is not known what the effect of taking Ruparib with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Rubraca® (rucaparib)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1116-1117